Table 1.
Clinicopathological description of non-small cell lung cancer cohort
| Variable | Stratification | #Cases SU2C Cohort |
| Age | <65 | 72 (49.3%) |
| ≥65 | 74 (50.7%) | |
| Gender | Male | 78 (49.1%) |
| Female | 81 (50.9%) | |
| Smoking | Smoker | 128 (81.0%) |
| Non-smoker | 30 (19.0%) | |
| Stage | I–II | 32 (20.4%) |
| III–IV | 125 (79.6%) | |
| Histology | Adenocarcinoma | 108 (73.0%) |
| Squamous | 40 (27.0%) | |
| PD-L1 status | PD-L1 <1% | 58 (41.4%) |
| PD-L1 ≥1% | 72 (58.6%) | |
| Treatment | Nivolumab | 126 (83.5%) |
| Pembrolizumab | 15 (9.9%) | |
| Atezolizumab | 10 (6.6%) |
PD-L1, programmed death ligand-1.